Short Interest in StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) Decreases By 22.4%

StageZero Life Sciences Ltd. (OTCMKTS:SZLSF) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 10,400 shares, a decline of 22.4% from the August 31st total of 13,400 shares. Based on an average daily volume of 1,200 shares, the short-interest ratio is presently 8.7 days.

StageZero Life Sciences Trading Down 76.0 %

Shares of StageZero Life Sciences stock opened at $0.04 on Friday. The business’s 50 day moving average price is $0.05 and its 200 day moving average price is $0.03. StageZero Life Sciences has a one year low of $0.00 and a one year high of $1.00.

StageZero Life Sciences Company Profile

StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood.